195 related articles for article (PubMed ID: 22820612)
1. Gastrointestinal-associated lymphoid tissue immune reconstitution in a randomized clinical trial of raltegravir versus non-nucleoside reverse transcriptase inhibitor-based regimens.
Asmuth DM; Ma ZM; Mann S; Knight TH; Yotter T; Albanese A; Melcher GP; Troia-Cancio P; Hayes T; Miller CJ; Pollard RB
AIDS; 2012 Aug; 26(13):1625-34. PubMed ID: 22820612
[TBL] [Abstract][Full Text] [Related]
2. Immune restoration in HIV-positive, antiretroviral-naive patients after 1 year of zidovudine/lamivudine plus nelfinavir or nevirapine.
Plana M; Ferrer E; Martínez C; Podzamczer D; García F; Maleno MJ; Barceló JJ; García A; Barberá MJ; Lacarcel M; Miró JM; Gallart T; Gatell JM
Antivir Ther; 2004 Apr; 9(2):197-204. PubMed ID: 15134181
[TBL] [Abstract][Full Text] [Related]
3. The effect of intensification with raltegravir on the HIV-1 reservoir of latently infected memory CD4 T cells in suppressed patients.
Vallejo A; Gutierrez C; Hernandez-Novoa B; Diaz L; Madrid N; Abad-Fernandez M; Dronda F; Perez-Elias MJ; Zamora J; Muñoz E; Muñoz-Fernandez MA; Moreno S
AIDS; 2012 Sep; 26(15):1885-94. PubMed ID: 22992577
[TBL] [Abstract][Full Text] [Related]
4. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
Li H; Zheng YH; Shen Z; Liu M; Liu C; He Y; Chen J; Ou QY; Huang ZL
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(42):2973-6. PubMed ID: 18261327
[TBL] [Abstract][Full Text] [Related]
5. Immune reconstitution after 2 years of successful potent antiretroviral therapy in previously untreated human immunodeficiency virus type 1-infected adults.
Notermans DW; Pakker NG; Hamann D; Foudraine NA; Kauffmann RH; Meenhorst PL; Goudsmit J; Roos MT; Schellekens PT; Miedema F; Danner SA
J Infect Dis; 1999 Oct; 180(4):1050-6. PubMed ID: 10479130
[TBL] [Abstract][Full Text] [Related]
6. Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study.
Llibre JM; Buzón MJ; Massanella M; Esteve A; Dahl V; Puertas MC; Domingo P; Gatell JM; Larrouse M; Gutierrez M; Palmer S; Stevenson M; Blanco J; Martinez-Picado J; Clotet B
Antivir Ther; 2012; 17(2):355-64. PubMed ID: 22290239
[TBL] [Abstract][Full Text] [Related]
7. Raltegravir intensification shows differing effects on CD8 and CD4 T cells in HIV-infected HAART-suppressed individuals with poor CD4 T-cell recovery.
Massanella M; Negredo E; Puig J; Puertas MC; Buzón MJ; Pérez-Álvarez N; Carrillo J; Clotet B; Martínez-Picado J; Blanco J
AIDS; 2012 Nov; 26(18):2285-93. PubMed ID: 23018435
[TBL] [Abstract][Full Text] [Related]
8. Reductions in viral load and increases in T lymphocyte numbers in treatment-naive patients with advanced HIV-1 infection treated with ritonavir, zidovudine and zalcitabine triple therapy.
Mathez D; Bagnarelli P; Gorin I; Katlama C; Pialoux G; Saimot G; Tubiana P; De Truchis P; Chauvin JP; Mills R; Rode R; Clementi M; Leibowitch J
Antivir Ther; 1997 Jul; 2(3):175-83. PubMed ID: 11322272
[TBL] [Abstract][Full Text] [Related]
9. Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV type 1-infected patients using a nonnucleoside reverse transcriptase inhibitor-based or a boosted protease inhibitor-based antiretroviral regimen: three-year results (The Advanz Trial): a randomized, controlled trial.
Miró JM; Manzardo C; Pich J; Domingo P; Ferrer E; Arribas JR; Ribera E; Arrizabalaga J; Loncá M; Cruceta A; de Lazzari E; Fuster M; Podzamczer D; Plana M; Gatell JM;
AIDS Res Hum Retroviruses; 2010 Jul; 26(7):747-57. PubMed ID: 20624069
[TBL] [Abstract][Full Text] [Related]
10. Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial.
Serrano-Villar S; Sainz T; Ma ZM; Utay NS; Chun TW; Mann S; Kashuba AD; Siewe B; Albanese A; Troia-Cancio P; Sinclair E; Somasunderam A; Yotter T; Deeks SG; Landay A; Pollard RB; Miller CJ; Moreno S; Asmuth DM
PLoS Pathog; 2016 Jan; 12(1):e1005381. PubMed ID: 26795282
[TBL] [Abstract][Full Text] [Related]
11. Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function.
Imaz A; Olmo M; Peñaranda M; Gutiérrez F; Romeu J; Larrousse M; Domingo P; Oteo JA; Curto J; Vilallonga C; Masiá M; López-Aldeguer J; Iribarren JA; Podzamczer D;
Antivir Ther; 2013; 18(1):125-30. PubMed ID: 22805174
[TBL] [Abstract][Full Text] [Related]
12. Impaired CD4+ T-cell restoration in the small versus large intestine of HIV-1-positive South Africans receiving combination antiretroviral therapy.
Cassol E; Malfeld S; Mahasha P; Bond R; Slavik T; Seebregts C; Poli G; Cassol S; van der Merwe SW; Rossouw T
J Infect Dis; 2013 Oct; 208(7):1113-22. PubMed ID: 23749968
[TBL] [Abstract][Full Text] [Related]
13. Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trial.
Byakwaga H; Kelly M; Purcell DF; French MA; Amin J; Lewin SR; Haskelberg H; Kelleher AD; Garsia R; Boyd MA; Cooper DA; Emery S;
J Infect Dis; 2011 Nov; 204(10):1532-40. PubMed ID: 21930607
[TBL] [Abstract][Full Text] [Related]
14. T cell proliferation and apoptosis in HIV-1-infected lymphoid tissue: impact of highly active antiretroviral therapy.
Dyrhol-Riise AM; Ohlsson M; Skarstein K; Nygaard SJ; Olofsson J; Jonsson R; Asjö B
Clin Immunol; 2001 Nov; 101(2):180-91. PubMed ID: 11683577
[TBL] [Abstract][Full Text] [Related]
15. Combination antiretroviral therapy with raltegravir leads to rapid immunologic reconstitution in treatment-naive patients with chronic HIV infection.
Pallikkuth S; Fischl MA; Pahwa S
J Infect Dis; 2013 Nov; 208(10):1613-23. PubMed ID: 23922374
[TBL] [Abstract][Full Text] [Related]
16. Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection.
Puertas MC; Massanella M; Llibre JM; Ballestero M; Buzon MJ; Ouchi D; Esteve A; Boix J; Manzardo C; Miró JM; Gatell JM; Clotet B; Blanco J; Martinez-Picado J;
AIDS; 2014 Jan; 28(3):325-34. PubMed ID: 24185044
[TBL] [Abstract][Full Text] [Related]
17. Early antiretroviral therapy with raltegravir generates sustained reductions in HIV reservoirs but not lower T-cell activation levels.
Hey-Cunningham WJ; Murray JM; Natarajan V; Amin J; Moore CL; Emery S; Cooper DA; Zaunders J; Kelleher AD; Koelsch KK;
AIDS; 2015 May; 29(8):911-9. PubMed ID: 25730509
[TBL] [Abstract][Full Text] [Related]
18. [Dynamics of T lymphocyte subsets in HAART treated AIDS patients with successful suppression of HIV replication and different CD4 + T cell restoration].
Qiu ZF; Li TS; Ruan GR; Han Y; Xie J; Zuo LY; Li YL; Wang AX
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Jun; 28(3):386-90. PubMed ID: 16900640
[TBL] [Abstract][Full Text] [Related]
19. A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load.
Arranz Caso JA; López JC; Santos I; Estrada V; Castilla V; Sanz J; Sanz J; Molina JP; Fernández Guerrero M; Górgolas M
HIV Med; 2005 Sep; 6(5):353-9. PubMed ID: 16156884
[TBL] [Abstract][Full Text] [Related]
20. Distinct mechanisms for mitochondrial DNA loss in T and B lymphocytes from HIV-infected patients exposed to nucleoside reverse-transcriptase inhibitors and those naive to antiretroviral treatment.
Maagaard A; Holberg-Petersen M; Løvgården G; Holm M; Pettersen FO; Kvale D
J Infect Dis; 2008 Nov; 198(10):1474-81. PubMed ID: 18851688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
